Tweet
Analysts forecast that Krystal Biotech Inc (NASDAQ:KRYS) will announce earnings per share of ($0.31) for the current fiscal quarter, according to Zacks . Zero analysts have made estimates for Krystal Biotech's earnings. Krystal Biotech reported earnings per share of ($1.26) during the same quarter last year, which would suggest a positive year over year growth rate of 75.4%. The company is scheduled to issue its next quarterly earnings report on Monday, November 12th.
On average, analysts expect that Krystal Biotech will report full year earnings of ($1.04) per share for the current year, with EPS estimates ranging from ($1.13) to ($0.92). For the next financial year, analysts expect that the business will report earnings of ($1.52) per share, with EPS estimates ranging from ($1.75) to ($1.26). Zacks' EPS calculations are a mean average based on a survey of sell-side research firms that cover Krystal Biotech. Get Krystal Biotech alerts:
Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, August 6th. The company reported ($0.22) EPS for the quarter, topping the Zacks' consensus estimate of ($0.34) by $0.12. A number of equities research analysts have recently issued reports on KRYS shares. LADENBURG THALM/SH SH set a $38.00 target price on shares of Krystal Biotech and gave the company a "buy" rating in a report on Thursday, July 19th. Chardan Capital started coverage on shares of Krystal Biotech in a report on Thursday, June 28th. They issued a "buy" rating and a $35.00 target price on the stock. Zacks Investment Research raised shares of Krystal Biotech from a "hold" rating to a "buy" rating and set a $18.00 target price on the stock in a report on Saturday, August 11th. William Blair started coverage on shares of Krystal Biotech in a report on Monday, August 6th. They issued a "buy" rating on the stock. Finally, ValuEngine raised shares of Krystal Biotech from a "sell" rating to a "hold" rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. The company has an average rating of "Buy" and a consensus price target of $30.33.
Shares of KRYS stock opened at $15.43 on Tuesday. The stock has a market capitalization of $165.77 million and a PE ratio of -10.74. Krystal Biotech has a 52-week low of $8.03 and a 52-week high of $19.25.
In related news, CFO Antony A. Riley purchased 2,800 shares of the stock in a transaction on Tuesday, May 22nd. The shares were purchased at an average cost of $10.75 per share, with a total value of $30,100.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website . Also, COO Suma Krishnan purchased 25,000 shares of the stock in a transaction on Wednesday, June 6th. The stock was bought at an average cost of $11.02 per share, for a total transaction of $275,500.00. The disclosure for this purchase can be found here . 45.80% of the stock is currently owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. raised its holdings in Krystal Biotech by 75.4% in the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company's stock valued at $194,000 after acquiring an additional 5,607 shares during the period. Acadian Asset Management LLC raised its holdings in Krystal Biotech by 552.2% in the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company's stock valued at $182,000 after acquiring an additional 10,331 shares during the period. Finally, Millennium Management LLC bought a new position in Krystal Biotech in the 4th quarter valued at about $266,000. 29.92% of the stock is currently owned by hedge funds and other institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Get a free copy of the Zacks research report on Krystal Biotech (KRYS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter 